Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A non-steroidal anti-inflammatory derivative of propionic acid with prostaglandin inhibitory effect due to non-selective inhibition of cyclo-oxygenase, used in the oral and topical treatment of pain and inflammatory and febrile processes.
Oral administration, one to three times a day.
Since the last update date we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data - high percentage of protein binding, short life (DrugInfo 2018, Helmy 2013, Jhee 2007) and low pKa - means it is unlikely for there to be transfer to milk in significant amounts.
Until there is more published data on this drug in relation to breastfeeding, safer alternatives may be preferred, especially during the neonatal period and in cases of prematurity.